BREAST CANCER
Conditions
Keywords
Breast Cancer, Advanced Breast Cancer
Brief summary
The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.
Detailed description
We want to determine the effects of Herceptin and to determine its efficacy in women with HER-2 overexpressing advanced breast cancer. The end-points will include the comparison of an array of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin. The other aim of this study would be to determine clinical response to therapy with Herceptin and Taxotere.
Interventions
DRUGHerceptin
IV
Sponsors
Genentech, Inc.
Mothaffar Rimawi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* All patients must be female. * Informed consent must be signed. * Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size \> 4 cm, and/or are deemed surgically inoperable. * Her2/neu overexpressing tumors defined as HercepTest score of 3+, or \>/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive. * Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential. * Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal. * Performance status (World Health Organization \[WHO\] scale) \< 2 and life expectancy \> 6 months. * Age \> 18. * No metastatic disease without concomitant primary breast cancer. * No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
Exclusion criteria
* Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential. * Severe underlying chronic illness or disease. * Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) \< 50%. * Patients on other investigational drugs while on study. * Severe or uncontrolled hypertension defined as blood pressure (BP) \> 180/100 on three separate occasions. * History of congestive heart failure. * History of coronary arterial disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The effects of Herceptin and its efficacy in women with HER-2 overexpressing advanced breast cancer | 1 year | A comparison of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin |
Secondary
| Measure | Time frame |
|---|---|
| To determine clinical response to therapy with Herceptin and Taxotere | one year |
Countries
United States
Outcome results
None listed